For more on Risk Assessment
at Fox Chase Cancer Center,
call 1-877-627-9684.

Department of Clinical Genetics

The Department of Clinical Genetics is built on the success of Fox Chase's Margaret Dyson Family Risk Assessment Program, which Dr. Mary Daly began in 1991. A high risk screening clinic was developed for individuals with a family history of breast or ovarian cancer. In addition to the clinic, genetic counseling was provided for both high risk and breast and ovarian cancer patients. As the clinic developed we also learned the importance of consultations for biopsy findings that put women at increased risk. 

The program was one of the first such programs in the nation to offer screening, education, and counseling to healthy people at increased genetic risk for disease. Since 1991, Fox Chase has expanded risk assessment services to those at high risk for melanoma, gastrointestinal or prostate cancers.

The Department of Clinical Genetics is closely aligned with ongoing research initiatives in Fox Chase's Cancer Prevention and Control Program, as well as its Keystone Program in Personalized Risk and Prevention, a collaborative translational science program co-led by Daly and funded through philanthropic donations to Fox Chase.

Faculty

Angela R. Bradbury, MD
Director, Breast and Ovarian Cancer Risk
Dr. Bradbury is an expert in breast cancer, cancer risk assessment and prevention, hereditary cancer syndromes and medical ethics. Her current research includes studying how and when parents communicate their BRCA (breast cancer gene) mutation status to their children and the impact of early communication of genetic risk on children's health behaviors.

Veda N. Giri, MD
Director, Prostate Cancer Risk
Dr. Giri is Assistant Professor in Cancer Prevention and Control, Medical Oncology, and Clinical Genetics. Her clinical expertise is in the areas of breast cancer; prostate cancer; and cancer genetics.

Dr. Giri’s research interests include the genetic, molecular and proteomic pathways involved in cancer susceptibility, especially prostate cancer.

Michael J. Hall, MD
Director, Gastrointestinal Risk
Dr. Hall specializes in cancers of the gastrointestinal (GI) tract, with a specific interest in pancreas, small bowel, and colon tumors. Dr. Hall's recent research has focused on the risk of pancreatic cancer in BRCA 1/2 mutation carriers, risk communication, racial/ethnic disparities in genetic testing, and the costs and benefits of pharmacogenomic and other genetic testing in the treatment of cancer.